Key result
Dalteparin was similarly effective as enoxaparin for VTE prophylaxis, with no significant differences in VTE or bleeding rates, while achieving $40,788 in savings over 6 months.
Why the study?
Does dalteparin compared to enoxaparin prevent VTE in hospitalized patients at risk?
Population
Hospitalized patients at risk of venous thromboembolism
Comparison
Dalteparin for VTE prophylaxis vs Enoxaparin for VTE prophylaxis
Design
Cohort
Follow-up
In-hospital
Authors
Loading...
May support dalteparin interchange for VTE prophylaxis with cost savings; hypothesis-generating pending randomized confirmation.
Cohort (n=3,509)
Does dalteparin compared to enoxaparin prevent VTE in hospitalized patients at risk?
A therapeutic interchange from enoxaparin to dalteparin for VTE prophylaxis in hospitalized patients maintains clinical efficacy and safety while providing cost savings.
Carson et al. (2011) conducted a cohort in Venous thromboembolism (VTE) risk (n=3,509). Dalteparin vs. Enoxaparin was evaluated on VTE rates. Dalteparin was similarly effective as enoxaparin for VTE prophylaxis, with no significant differences in VTE or bleeding rates, while achieving $40,788 in savings over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: